Severe treatment-related side effects were more common in the combination therapy group, with hypertension and decreased platelet count being the most frequent. For patients with unresectable, ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer ... but considerable side effects that forced a dosing change that has delayed a final readout.

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

NIH researchers discovered that a new form of personalized cancer immunotherapy dramatically improved the treatment’s ...